Latest period
$641M
YoY change
-1192.7%
5Y CAGR
—
Peak year (FY2025)
$465M
Latest annual
$465M
Free Cash Flow history chart for Alnylam Pharmaceuticals (ALNY) from 2016 to 2025
Latest: $465M
Free Cash Flow growth chart for Alnylam Pharmaceuticals (ALNY) from 2016 to 2025
Latest: -1192.7%
Free Cash Flow history table for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
| FY2025 | $465M | -1192.7% | +$508M | ||
| FY2024 | -$42.6M | -201.5% | -$84.5M | ||
| FY2023 | $41.9M | -106.8% | +$655M | ||
| FY2022 | -$613M | -14.6% | +$105M | ||
| FY2021 | -$718M | +4.8% | -$32.7M | ||
| FY2020 | -$685M | +63.7% | -$267M | ||
| FY2019 | -$419M | -39.3% | +$271M | ||
| FY2018 | -$690M | +41.6% | -$203M | ||
| FY2017 | -$487M | +30.8% | -$115M | ||
| FY2016 | -$372M | +84.2% | -$170M | ||
| FY2015 | -$202M | +15.7% | -$27.5M | ||
| FY2014 | -$175M | +140.3% | -$102M | ||
| FY2013 | -$72.7M | -41.4% | +$51.3M | ||
| FY2012 | -$124M | +40.3% | -$35.6M | ||
| FY2011 | -$88.4M | -0.8% | +$714K | ||
| FY2010 | -$89.1M | +15.5% | -$12M | ||
| FY2009 | -$77.1M | -240.9% | -$132M | ||
| FY2008 | $54.7M | -71.0% | -$134M | ||
| FY2007 | $189M | -737.3% | +$218M | ||
| FY2006 | -$29.6M | +60.7% | -$11.2M | ||
| FY2005 | -$18.4M | -35.5% | +$10.1M | ||
| FY2004 | -$28.6M | +79.2% | -$12.6M | ||
| FY2003 | -$15.9M | +766.7% | -$14.1M | ||
| FY2002 | -$1.84M | — | — |
- FY2025$465M-1192.7%
- FY2024-$42.6M-201.5%
- FY2023$41.9M-106.8%
- FY2022-$613M-14.6%
- FY2021-$718M+4.8%
- FY2020-$685M+63.7%
- FY2019-$419M-39.3%
- FY2018-$690M+41.6%
- FY2017-$487M+30.8%
- FY2016-$372M+84.2%
- FY2015-$202M+15.7%
- FY2014-$175M+140.3%
- FY2013-$72.7M-41.4%
- FY2012-$124M+40.3%
- FY2011-$88.4M-0.8%
- FY2010-$89.1M+15.5%
- FY2009-$77.1M-240.9%
- FY2008$54.7M-71.0%
- FY2007$189M-737.3%
- FY2006-$29.6M+60.7%
- FY2005-$18.4M-35.5%
- FY2004-$28.6M+79.2%
- FY2003-$15.9M+766.7%
- FY2002-$1.84M—
Free Cash Flow values are taken from Alnylam Pharmaceuticals's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Free Cash Flow at Alnylam Pharmaceuticals (ALNY)
Free Cash Flow for Alnylam Pharmaceuticals (ALNY): headline value $641M · YoY -1,192.7%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
Alnylam Pharmaceuticals (ALNY) most recent annual free cash flow stands at $465M (2025) – plunged 1192.7% year-over-year.
2025 marks the peak free cash flow at $465M, with the historical low of -$718M recorded in 2021.
Alnylam Pharmaceuticals Free Cash Flow by Year
Alnylam Pharmaceuticals Free Cash Flow 2025: $465M
Alnylam Pharmaceuticals posted free cash flow of $465M in 2025, plunged 1192.7% below 2024. This figure represents the highest annual value in the available history.
Alnylam Pharmaceuticals Free Cash Flow 2024: -$42.6M
In 2024, Alnylam Pharmaceuticals reported free cash flow of -$42.6M, plunged 201.5% below 2023.
Alnylam Pharmaceuticals Free Cash Flow 2023: $41.9M
Alnylam Pharmaceuticals free cash flow in 2023 was $41.9M, plunged 106.8% below 2022.
Alnylam Pharmaceuticals Free Cash Flow 2022: -$613M
2022's free cash flow for Alnylam Pharmaceuticals came in at -$613M, declined 14.6% below 2021.
Alnylam Pharmaceuticals Free Cash Flow 2021: -$718M
Alnylam Pharmaceuticals free cash flow in 2021 was -$718M.
See more financial history for Alnylam Pharmaceuticals (ALNY).
Sector peers by Free Cash Flow
Healthcare peers of Alnylam Pharmaceuticals (ALNY), ranked by their latest free cash flow
| $19.7B | |
| $17.8B | |
| $16.1B | |
| $12.4B | |
| $8.97B | |
| $8.1B | |
| $6.29B | |
| $4.52B |
- $19.7B
- $17.8B
- $16.1B
- $12.4B
- $8.97B
- $8.1B
- $4.52B
Frequently asked questions
Alnylam Pharmaceuticals (ALNY) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
How this company returns cash to shareholders — buybacks, dividends, and stock splits.